logo
logo

Lidds Secures Financing Of Up To 40.8 Msek To Create Foundation For New Partnerships Based On The Nanozolid® Technology

Feb 22, 2022over 3 years ago
UppsalaBiotechnology

Description

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the company has entered into a convertible note agreement with Nice & Green (“N&G”), a Swiss specialty investor with significant experience from the life science industry. N&G has committed to subscribe for convertible notes with a nominal value of up to 40.8 MSEK. LIDDS has the option, but not the obligation, to use the agreed financing during the next 18 months, bringing flexibility to the company and creating foundation for new partnerships based on the NanoZolid® technology.

Company Information

Company

Lidds

Location

Uppsala, Uppsala län, Sweden

About

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months.

Related People